Clinical Trial Update: ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial [Phase 3]

View source ↗

Summary

Phase 3 ORIENT trial studied olmesartan for reducing incidence of end-stage renal disease in adults with diabetic nephropathy; the study completed and results w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy
• Type 2 Diabetes Mellitus

Drugs mentioned

• Olmesartan (olmesartan)

Snippet

Sponsor: Daiichi Sankyo Co., Ltd. | Conditions: Diabetic Nephropathy, Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2011-05-10